Human TL1A-DR3 inhibition Kit (TR-FRET)

优势与特点（FAB）

1. Cost effective - Sufficient quantity at a lower price, accounting for dilution and pipetting losses.
2. Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
3. Simple and fast operation - No complicated washing steps, significantly reducing time.
4. High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
5. Accurate and reliable results - High sensitivity with minimal matrix effects.
6. High throughput capability - Supports 500 tests, ideal for high-throughput screening.
7. Fast completion - Results in just 1 hour.

产品参数（Product Specifications）

产品概述（Product Overview）

The Human TL1A-DR3 inhibition Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human TL1A binding to human DR3 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of TL1A to bind to human DR3.

存储（Storage）

2-8℃

组分（Materials Provided）

原理（Assay Principles）

This Human TL1A-DR3 inhibition kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human TL1A and Europium-chelate labeled streptavidin as the donor and FA labeled human DR3 protein as the acceptor.

- In the absence of inhibitors for human TL1A binding to human DR3, the donor and acceptor are in close proximity due to the binding of human TL1A and FA-labeled human DR3. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.

- In the presence of inhibitors that block the binding of human TL1A to human DR3, the donor-acceptor interaction is disrupted, preventing FRET from occurring.

质量管理控制体系（QMS）

1. 质量管理体系（ISO, GMP）
2. 质量优势
3. 质控流程